Mergers & Acquisitions ·
Glucotrack completes merger with Lokahi Therapeutics, raising $9.95M via bridge notes and PIPE
GCTKGlucotrack, Inc.
Glucotrack completed its acquisition of Lokahi Therapeutics on July 14, 2026, issuing shares representing 90% of the combined equity to former Lokahi holders in a transaction valued at approximately $33.3 million. The deal includes $25.4 million in in-process research and development assets and $14.7 million in goodwill. Concurrently, Glucotrack raised $9.95 million through two rounds of senior secured convertible bridge notes ($4.45 million and $3.5 million) and a $2 million interim PIPE financing via prefunded warrants at $11.25 per share. The company also entered into a $50 million equity line of credit. Glucotrack develops continuous glucose monitoring technology for diabetes management.